2nd Quarter - Report

AVENUE SOLUTIONS for GENENTECH USA, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program; Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress; Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress; Senate Finance Committee Drug Pricing Reform Principles; Possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services; Senate HELP and Energy & Commerce Public Option RFI

LobbyistCovered position, as disclosed
TRACY SPICER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Issues related to Medicare Part B, CMS coverage and reimbursement, 340b drug pricing program; Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress; Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress; Senate Finance Committee Drug Pricing Reform Principles

LobbyistCovered position, as disclosed
TRACY SPICER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Issues related to tax policy

LobbyistCovered position, as disclosed
TRACY SPICER —
AMY TEJRAL New Legislative Director, Sen. Ben Nelson

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.